Ever wonder why your team is spending hours just checking patent statusonly to discover later that the work was either incomplete, duplicated, or out-of-date?
Thats not a minor workflow problem. Its a cost problem.
In the latest DrugPatentWatch blog, t…

A spreadsheet of drug patent expiration dates can feel like a strategy.
It often starts with good intentions: Lets list every key date, track every filing, and be ready before the competition arrives. In a spreadsheet, expiration looks like a finish li…

A piece of fast market intelligence costing three weeks is not a minor delayits a structural problem.
Thats the message behind a recent DrugPatentWatch analysis of a workflow that should have taken hours, but instead took weeks. And if you work anywher…

Companies dont usually miss NCE-1 dates because they cant find them. They miss them because they treat regulatory intelligence like a quarterly report instead of a live operating system.
Thats the core warning behind DrugPatentWatchs latest piece on wh…

Stop Searching for Patents. Start Asking Them Questions.
Most people do patent searching the way they shop for a used car: they browse, they compare, they hope something jumps outthen they move on when it doesnt feel obvious enough.
In life sciences, t…

Your competitive intelligence team is still reading PACER by hand. Heres the costin reaction time.
If youre relying on manual PACER pulls, spreadsheets, and copy‑paste triage, youre not just being careful. Youre building a system that cant keep up wi…

📌 Most people think they understand generic launches because of patent expiration dates. They dont.
The premise feels intuitive: Once key patents expire, generics should rush in. But real-world drug launches dont behave like a simple calendar countd…

Pharma keeps telling the same bedtime story: The patent cliff is coming.
That cliffwhere blockbuster revenues supposedly drop overnightis the myth many models still use to forecast the industrys future.
But if you actually look at how drug exclusivity …

The Real Patent Isnt the One Everyone FightsIts the One Nobody Challenges.
If you follow pharma, youve seen the headlines: blockbuster drug challenged, court dates set, litigation teams assembled, stakeholders watching for the next procedural twist. …

A surprising (and uncomfortable) takeaway from recent pharma IP litigation: strong patents dont automatically winenforceable IP does.
That distinction sounds subtle until youre the one trying to turn a thick stack of filings into real leverage in court…